DIFFERENTIAL EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATOR RECEPTOR (PPAR) ALPHA AND GAMMA AGONISTS ON BODY WEIGHT AND ADIPOSE DEPOTS IN FRUCTOSE FED WISTAR RATS

  • Emilija Atanasovska MD, PhD
  • Kristina Pavlovska Department of Preclinical and Clinical Pharmacology and Toxicology, Medical Faculty, Skopje
  • Krume Jakjovski
  • Kalina Gjorgjievska Department of Preclinical and Clinical Pharmacology and Toxicology, Medical Faculty, Skopje
  • Dragica Zendelovska
  • Marija Petrushevska Department of Preclinical and Clinical Pharmacology and Toxicology, Medical Faculty, Skopje
  • Irfan Ahmeti University Clinic of Endocrinology, Diabetes and Metabolic Disorders, Faculty of Medicine, Skopje
  • Dimce Zafirov Department of Preclinical and Clinical Pharmacology and Toxicology, Medical Faculty, Skopje
  • Nikola Labacevski Department of Preclinical and Clinical Pharmacology and Toxicology, Medical Faculty, Skopje

Abstract

Aims: To investigate the effect of fenofibrate (PPAR-alpha agonist) and rosiglitazone (PPAR-gamma agonist) on body weight and adipose depots in an experimental model of the metabolic syndrome.


Methods: Metabolic syndrome was induced in 48 male Wistar rats by adding a fructose in drinking water (10% solution) for 12 weeks. During the last 4 weeks, 16 rats were treated with fenofibrate (100 mg/kg/day), 16 rats were treated with rosiglitazone (5 mg/kg/day) by intragastric tube, while the remaining 16 did not receive any medication (fructose group). Another control group of 16 rats consumed standard rat chow and water for 12 weeks.


Results: Chronic fructose administration for 12 weeks significantly increased the body weight (p<0.05), as well as the weight of the measured fat pads: perirenal (p<0.001) and epididymal (p<0.001) as representatives of the visceral adipose depots and the inguinal pads (p<0.05) as a representative of the subcutaneous adipose depots compared to the control group. This was accompanied with a decrease of the subcutaneous/visceral fat ratio. Treatment with fenofibrate over the final 4 weeks significantly decreased the body weight (p<0.001) and the weight of the epididymal, perirenal and inguinal fat pads (p<0.001 for all parameters), without changes of the subcutaneous/visceral fat ratio.


On the other hand, rosiglitazone promoted weight gain. Treatment with this PPAR-gamma agonist significantly decreased the weight of the epididymal (p<0.01) and perirenal (p<0.05) pads, but increased the weight of the inguinal fat pads (p<0.001) compared to the fructose group, which led to an increase of the subcutaneous/visceral fat ratio.


Conclusion: This study indicates that treatment with the PPAR-alpha agonist fenofibrate decreases body weight and reduces the fat depots, whereas PPAR-gamma agonist promotes weight gain and a body fat redistribution from visceral towards subcutaneous depots in an animal nutritive model of the metabolic syndrome.


 Key words: fructose, fenofibrate, rosiglitazone, PPAR, metabolic syndrome, body weight

Published
2018-04-03
How to Cite
ATANASOVSKA, Emilija et al. DIFFERENTIAL EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATOR RECEPTOR (PPAR) ALPHA AND GAMMA AGONISTS ON BODY WEIGHT AND ADIPOSE DEPOTS IN FRUCTOSE FED WISTAR RATS. Journal of Morphological Sciences, [S.l.], v. 1, n. 1, p. 62-72, apr. 2018. ISSN 2545-4706. Available at: <https://jms.mk/jms/article/view/21>. Date accessed: 03 dec. 2022.
Section
Articles